In addition, given their putative role in the pathogenesis of NAFLD and its progression to HCC, TNF-α and adiponectin, which seem to antagonize each other, are potentially promising therapeutic targets to be evaluated in the setting of NAFLD-associated HCC, alone or, even better, in combination with systematic therapy, e.g., ICIs, which seem to be less effective in NAFLD-associated HCC than in non-NAFLD-HCC [16,83]. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.